SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: XenaLives who wrote (5477)1/19/2002 12:06:00 PM
From: michael97123  Respond to of 52153
 
"What's worse, some experts now say that if the trials are structured the way the FDA wants them structured, ImClone could wind up losing its patent protection on the drug."

Paula,
From the article you posted perhaps another nail in the coffin. mike



To: XenaLives who wrote (5477)1/19/2002 12:25:38 PM
From: Casaubon  Respond to of 52153
 
anyone know why they might lose thier patent protection if the trials are structured different? I've never heard of such a thing and can't imagine how the structure of a clinical trial can have any bearing on the validity of a patent.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News